New Therapy May Cure Autoimmune Diseases Without Chemo

Millions of Americans living with autoimmune diseases just got a major dose of hope.

The FDA has cleared a groundbreaking new therapy for human testing that could cure conditions like lupus, rheumatoid arthritis, and systemic sclerosis without the dangerous chemotherapy currently required. The Calibr-Skaggs Institute for Innovative Medicines at Scripps Research will soon begin recruiting patients for the phase 1 trial.

The therapy, called sCAR-T, builds on an existing treatment that has already shown curative potential in autoimmune diseases. Traditional CAR-T therapy works by resetting the entire immune system, helping patients escape the cycle of lifelong immune-suppressing drugs. But there's been a painful catch: patients must first undergo lymphodepletion, a harsh chemotherapy procedure that wipes out existing immune cells and leaves people vulnerable to dangerous infections.

The new switchable version changes everything. By using two components that work together, a specially designed T cell and a protein "switch," the therapy can do its job without chemotherapy. Early results in cancer patients show the approach already works, with cells expanding even more effectively than approved treatments.

The phase 1 trial will test safety and effectiveness in patients with myositis, systemic sclerosis, lupus, and rheumatoid arthritis. If successful, the treatment could expand to other autoimmune conditions affecting up to 12% of people worldwide.

Travis Young, vice president of biologics at Calibr-Skaggs, explains the stakes: "Patients with chronic autoimmune diseases need curative options that do not require life-long immunosuppressive therapy to manage their condition." The new therapy has the potential to transform treatment by eliminating chemotherapy-associated risks entirely.

The Ripple Effect

This isn't just about avoiding chemotherapy side effects. By removing that barrier, the therapy could reach far more patients who currently can't access CAR-T treatment because they're too sick for chemo or live too far from specialized centers. Making curative treatment accessible to a broader population means fewer people trapped in cycles of expensive medications, hospital visits, and progressive disease.

Chief Medical Officer Chan Beals sees the bigger picture: successfully proving this works for conditions like lupus and rheumatoid arthritis could open doors for treating many other autoimmune diseases, bringing hope to countless more patients in the future.

Patient enrollment begins soon, and interested participants or doctors can find information at calibr.scripps.edu or search for trial NCT06913608 on clinicaltrials.gov.